General Information
Drug ID
DR01433
Drug Name
Atrasentan
Synonyms
Xinlay; Atrasentan [INN]; A 127722; A 147627; ABT 627; A-127722; A-147627; ABT-627; Xinlay (TN); A-127722.5; (+)-A 127722; (+)-A-127722; (11C)ABT-627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid
Drug Type
Small molecular drug
Indication Endothelial dysfunction [ICD11: BE2Z] Phase 3 [1]
Structure
3D MOL 2D MOL
Formula
C29H38N2O6
Canonical SMILES
CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
InChI
InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
InChIKey
MOTJMGVDPWRKOC-QPVYNBJUSA-N
CAS Number
CAS 195733-43-8
Pharmaceutical Properties Molecular Weight 510.6 Topological Polar Surface Area 88.5
Heavy Atom Count 37 Rotatable Bond Count 12
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
XLogP
2.4
PubChem CID
159594
PubChem SID
535748 , 10253652 , 12014999 , 14811316 , 14909273 , 46234806 , 50068170 , 50253083 , 53788137 , 53789849 , 57348721 , 103168476 , 103948098 , 113442732 , 127346318 , 128626310 , 134338952 , 134339653 , 135115498 , 135325628 , 137006712 , 141972835 , 163620866 , 163686195 , 178100477 , 179150068 , 185974011 , 198977266 , 224005477 , 226421083
ChEBI ID
CHEBI:135810
TTD Drug ID
D0Y6UU
DT(s) Transporting This Drug OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [2]
References
1 ClinicalTrials.gov (NCT00271492) Correlation of Endothelial Function and Early Coronary Artery Disease in Humans
2 Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
3 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.